The anticoagulant effect of heparin during radiofrequency ablation (RFA) in patients taking apixaban or rivaroxaban.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 28735423)

Published in J Interv Card Electrophysiol on July 22, 2017

Authors

L C Brendel1, F Dobler1, G Hessling1, J Michel1, S L Braun1, A L Steinsiek1, P Groha1, R Eckl1, I Deisenhofer1, A Hyseni2, M Roest2, I Ott1, B Steppich3

Author Affiliations

1: Deutsches Herzzentrum der Technischen Universität München, Lazarettstr. 36, 80636, Munich, Germany.
2: Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht, The Netherlands.
3: Deutsches Herzzentrum der Technischen Universität München, Lazarettstr. 36, 80636, Munich, Germany. birgitsteppich@yahoo.de.

Articles cited by this

Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA (2003) 4.74

Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.36

In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor. J Thromb Haemost (2005) 2.16

Beyond unfractionated heparin and warfarin: current and future advances. Circulation (2007) 1.52

A comparison of bleeding complications post-ablation between warfarin and dabigatran. J Interv Card Electrophysiol (2012) 1.08

Safety of continuous periprocedural rivaroxaban for patients undergoing left atrial catheter ablation procedures. Circ Arrhythm Electrophysiol (2014) 1.01

Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review. Thromb Res (2015) 0.99

Facts and artefacts of coagulation assays for factor Xa inhibitors. Thromb Haemost (2010) 0.97

Atrial fibrillation therapy now and in the future: drugs, biologicals, and ablation. Circ Res (2014) 0.97

Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon. Am J Cardiol (2014) 0.97

Coagulation assessment with the new generation of oral anticoagulants. Emerg Med J (2015) 0.93

Increased mortality in systemic inflammatory response syndrome patients with high levels of coagulation factor VIIa. J Thromb Haemost (2013) 0.88

A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation. J Interv Card Electrophysiol (2014) 0.86

NOACs versus warfarin for stroke prevention in patients with AF: a systematic review and meta-analysis. Open Heart (2016) 0.84

Heparin-Calibrated Chromogenic Anti-Xa Activity Measurements in Patients Receiving Rivaroxaban: Can This Test Be Used to Quantify Drug Level? Ann Pharmacother (2015) 0.83

Uninterrupted New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Ablation of Atrial Fibrillation: A Meta-analysis. Can J Cardiol (2015) 0.83

A head-to-head comparison of periprocedural coagulability under anticoagulation with rivaroxaban versus dabigatran in patients undergoing ablation of atrial fibrillation. Clin Drug Investig (2013) 0.81

Advances in atrial fibrillation ablation. J Invasive Cardiol (2009) 0.80